Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

J&J under fire from 170 nonprofits to halt baby powder sales worldwide because it contains asbestos

July 9, 2020
Sales and Marketing Cancer, J&J, JJ, pharma, talc

In the latest chapter in Johnson & Johnson’s talc-related woes, the company is being pressured by group of over 170 …

News
european_commission_web

European green light for Lynparza in germline BRCA-mutated metastatic pancreatic cancer

July 8, 2020
Research and Development, Sales and Marketing AstraZeneca, Cancer, Europe, MSD, lynparza

The European Commission has awarded approval to AstraZeneca and MSD’s Lynparza (olaparib) for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer, with …

News
shutterstock_3

COVID-19 impact on England’s cancer services could lead to 35,000 excess deaths

July 8, 2020
Research and Development COVID-19, Cancer, England, coronavirus

New data emerging from DATA-CAN: The Health Data Research Hub for Cancer has shone a light on the potential toll …

News

Roche’s Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3

June 19, 2020
Medical Communications, Research and Development Cancer, Genentech, Roche, breast cancer, tecentriq

 

News

FDA approval for Jazz and PharmaMar’s Zepzelca in metastatic small cell lung cancer

June 17, 2020
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, FDA, PharmaMar, Zepzelca, jazz pharma, lung cancer

The FDA has awarded approval to Jazz Pharma and PharmaMar for Zepzelca (lurbinectedin) as a treatment for metastatic small cell …

News
gilead-sciences

Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020

June 1, 2020
Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab

Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …

News
lynparza

Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer

June 1, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza

Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …

News
fda2outsideweb

Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer

May 11, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer

Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …

News

NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population

May 7, 2020
Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …

News
shutter

Sanofi and Regeneron’s Libtayo shows durable responses in world’s most common skin cancer

May 5, 2020
Manufacturing and Production, Research and Development Cancer, Libtayo, Regeneron, Sanofi

Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with …

News
shutterstock

Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer

April 29, 2020
Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer

A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …

News

FDA approves Immunomedics’ Trodelvy for metastatic triple-negative breast cancer one month ahead of schedule

April 23, 2020
Sales and Marketing Cancer, Immunomedics, Trodelvy, breast cancer, pharma

Immunomedics has scored approval with the FDA for Trodelvy (sacituzumab govitecan-hziy) in the treatment of metastatic triple-negative breast cancer, it …

News
abbvie_0

AbbVie’s Imbruvica scoops up 11th FDA approval with chronic lymphocytic leukaemia/small lymphocytic lymphoma nod

April 22, 2020
Research and Development, Sales and Marketing Cancer, FDA, imbruvica, leukaemia

AbbVie’s Imbruvica (ibrutinib) has scored its 11th FDA approval, this time in combination with rituximab for the treatment of chronic …

News

Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer

April 21, 2020
Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …

News
fda2outsideweb

FDA approves UroGen’s Jelmyto as first therapy for low-grade upper tract urothelial cancer

April 16, 2020
Sales and Marketing Cancer, FDA, Jelmyto, UroGen Pharma, pharma, urothelial cancer

The FDA has moved to authorise UroGen Pharma’s Jelmyto (mitomycin gel) in the US for the treatment of low-grade upper …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026